Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors (PACAomics)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01692873|
Recruitment Status : Completed
First Posted : September 25, 2012
Last Update Posted : August 14, 2018
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Tumor||Procedure: suspected pancreatic tumor||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||274 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||December 2017|
|Actual Study Completion Date :||December 2017|
Experimental: suspected pancreatic tumor
Realization of pancreatic tumor biopsy and blood samples
Procedure: suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
- Biomarkers [ Time Frame: within twenty four hours ]Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
- Histology [ Time Frame: within twenty four hours ]To determine the histologic characteristics of the pancreatic tumor
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01692873
|Marine GILABERT, MD|
|Marseille, France, 13009|
|Principal Investigator:||Marine GILABERT, MD||Institut Paoli-Calmettes|